Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Randy Scott
AddedMar 31, 2024
UpdatedJun 28, 2026
Randy Scott

Randy Scott

Board Member, Talis Biomedical

CrunchbaseLinkedIn

Randy Scott's Career

Talis Biomedical
Talis Biomedical

Menlo Park, CA, US

Board Member· Board
BridgeBio Pharma
BridgeBio Pharma

Palo Alto, CA, US

Board Member· Board
Invitae
Invitae

San Francisco, CA, US

Board Member· Board
Genome Medical
Genome Medical

South San Francisco, CA, US

Board Member· Board
Freenome
Freenome

South San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Randy Scott's Career

Talis Biomedical
Talis Biomedical
Public$8.6M1022010Menlo Park, CA, US
Board Member· Board

Leadership at Talis Biomedical

Brian CoeBrian CoeCo-Founder
Rob KelleyRob KelleyCEO
Rustem IsmagilovRustem IsmagilovCo-Founder
Liang LiLiang LiCo-Founder

Similar to Talis Biomedical

InstadiagnosticsInstadiagnosticsPhiladelphia, PA, USDiagnostic Testsest. 2015InstadiagnosticsPhiladelphia, PA, US · est. 2015

Instadiagnostics: Bringing rapid, quantitative, bedside diagnostic testing to patients.

Pre-Seed · $6.7M7
Prompt DiagnosticsPrompt DiagnosticsBaltimore, MD, USDiagnostic TestsPrompt DiagnosticsBaltimore, MD, US

Prompt Diagnostics: Rapid, affordable, and precise biotech firm for easy-to-use diagnostic testing.

Pre-Seed · $600k2
TAI DiagnosticsTAI DiagnosticsWauwatosa, WI, USDiagnostic Testsest. 2013TAI DiagnosticsWauwatosa, WI, US · est. 2013

TAI Diagnostics: A Wisconsin-based biotech firm offering non-invasive, sensitive tests for transplant patients.

Series A · $29M11
Test DiagnosticsTest DiagnosticsNew York City, NY, USDiagnostics, Medical DevicesTest DiagnosticsNew York City, NY, US

NYC-based Test Diagnostics develops Point-of-Care diagnostic technology.

Seed · $334k2
BridgeBio Pharma
BridgeBio Pharma
Public$3.6B3922015Palo Alto, CA, US
Board Member· Board

Leadership at BridgeBio Pharma

Jennifer CookJennifer CookBoard Member
Richard SchellerRichard SchellerBoard Member
Jim MomtazeeJim MomtazeeBoard Member
Neil KumarNeil KumarFounder
Charles HomcyCharles HomcyBoard Member
Andrea EllisAndrea EllisBoard Member
Invitae
Invitae
Public$2.5B1.7k2010San Francisco, CA, US
Board Member· Board

Leadership at Invitae

Christine GorjancChristine GorjancBoard Member
Eric AguiarEric AguiarBoard Member
Geoffrey CrouseGeoffrey CrouseBoard Member
Kimber LockhartKimber LockhartBoard Member
Alex FurmanAlex FurmanCo-Founder
Jason MyersJason MyersBoard Member

Similar to Invitae

23andMe23andMeSunnyvale, CA, USGenetic Testingest. 200623andMeSunnyvale, CA, US · est. 2006

23andMe: A biotech firm offering direct-to-consumer genetic testing for ancestry and health predispositions.

Public · $1.1B816
Fulgent GeneticsFulgent GeneticsTemple City, CA, USGenetic Testingest. 2011Fulgent GeneticsTemple City, CA, US · est. 2011

Fulgent Genetics, Inc.: A biotech firm offering advanced genetic testing via proprietary technology.

Public1k
GeneticaGeneticaSan Francisco, CA, USGene Testingest. 2017GeneticaSan Francisco, CA, US · est. 2017

San Francisco-based Genetica pioneers in gene testing technology for precision medicine in Asia.

Seed · $2.5M75
ColorColorBurlingame, CA, USGenetic Testing, Health Informationest. 2015ColorBurlingame, CA, US · est. 2015

Color: A health tech firm providing genetic tests for disease risk and medication response analysis.

Series E · $482M474
Genome Medical
Genome Medical
Series C$120.4M1722016South San Francisco, CA, US
Board Member· Board

Leadership at Genome Medical

Lisa AldersonLisa AldersonCo-Founder
Robert GreenRobert GreenCo-Founder
Jessica ZeaskeJessica ZeaskeBoard Member
Nick NaclerioNick NaclerioBoard Member
Jill DaviesJill DaviesCEO
Tim HoweTim HoweBoard Member
Freenome
Freenome
Late Stage Private$1.1B3752014South San Francisco, CA, US
Board Member· Board

Recent news

Vijay Pande, founding partner of a16z bio and health strategy, steps downTechCrunch · 2025

Leadership at Freenome

Vijay PandeVijay PandeBoard Member
Gabriel OtteGabriel OtteCo-Founder
Mike NolanMike NolanCEO
Michael OtteMichael OtteCo-Founder
Riley EnnisRiley EnnisCo-Founder

Similar to Freenome

GRAILGRAILMenlo Park, CA, USCancer Detectionest. 2016GRAILMenlo Park, CA, US · est. 2016

GRAIL, Inc., a Menlo Park-based biotech firm, specializes in early cancer detection using science and technology.

Public · $2B823
OncodeaOncodeaSaint Paul, MN, USCancer Detectionest. 2021OncodeaSaint Paul, MN, US · est. 2021

Oncodea: Pioneering affordable, non-invasive cancer detection technology since 2021.

Angel · $6k7
Guardant HealthGuardant HealthPalo Alto, CA, USCancer Diagnosticsest. 2011Guardant HealthPalo Alto, CA, US · est. 2011

Guardant Health: A Palo Alto-based biotech firm providing global cancer diagnostics and sequencing services.

Public1.8k

Randy Scott's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Randy Scott

Stephane MarceauStephane MarceauCo-Founder · OMsignalScott RaffertyScott RaffertyCo-Founder · ConsensusScott GrahamScott GrahamCo-Founder · MimmerRobert SmithRobert SmithCo-Founder · Moov FinancialCharles ConnCharles ConnFounder · Monograph CapitalChuck DoyleChuck DoyleFounder & CEO · Business Capital